Screener
MoonLake Immunotherapeutics MLTX Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by MoonLake Immunotherapeutics in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 8:55 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001821586-26-000007
| (in thousands, except share and per share data) | March 31, 2026 (Unaudited) | December 31, 2025 |
|---|---|---|
| Commitments and contingencies (Note 15) | ||
| Shareholders' equity | ||
| Class A Ordinary Shares: $0.0001 par value per share; 500,000,000 shares authorized; 72,134,066 shares issued and outstanding as of March 31, 2026; 71,373,579 shares issued and outstanding as of December 31, 2025 | 7 | 7 |
| Additional paid-in capital | 786,313 | 766,781 |
| Accumulated deficit | (532,618) | (462,911) |
| Accumulated other comprehensive income | 322 | 604 |
| Total shareholders’ equity | 254,024 | 304,481 |
| Total liabilities and shareholders' equity | $400,374 | $424,433 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is MoonLake Immunotherapeutics's total equity?
- MoonLake Immunotherapeutics (MLTX) reported total equity of $254.02M in Q1 2026.
- How has MoonLake Immunotherapeutics's total equity changed year-over-year?
- MoonLake Immunotherapeutics's total equity decreased by 37.7% year-over-year, from $407.52M to $254.02M.
- What is the long-term trend for MoonLake Immunotherapeutics's total equity?
- Over 5 years (2020 to 2025), MoonLake Immunotherapeutics's total equity has grown at a 161.0% compound annual growth rate (CAGR), from -$2.52M to $304.48M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about MoonLake Immunotherapeutics's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude